GH Research (GHRS) Research & Development (2020 - 2025)
GH Research (GHRS) recorded quarterly Research & Development of -$66.1 million in Q4 2025, down 725.93% quarter-over-quarter from $10.6 million in Q3 2025, and down 6.98% on a YoY basis from -$71.1 million in Q4 2024.
GH Research (GHRS) Research & Development (2020 - 2025) Analysis & Trends
GH Research's Research & Development history runs 6 years deep, the most recent figure standing at -$66.1 million for Q4 2025.
- In Q4 2025, Research & Development fell 6.98% year-over-year to -$66.1 million; the TTM figure through Dec 2025 stood at -$38.8 million (down 10.71% YoY), while the FY2025 annual figure was -$38.8 million, down 10.71% from the prior year.
- Research & Development was -$66.1 million for Q4 2025 at GH Research, down from $10.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $13.8 million in Q4 2021 to a low of -$66.1 million in Q4 2025.
- Historically, Research & Development has averaged -$1.2 million across 5 years, with a median of $7.1 million in 2023.
- Biggest YoY gain for Research & Development was 3004.97% in 2021; the steepest drop was 4547.27% in 2021.
- A 5-year view of Research & Development shows it stood at $13.8 million in 2021, then sank by 49.76% to $6.9 million in 2022, then gained by 19.41% to $8.3 million in 2023, then sank by 849.32% to -$61.8 million in 2024, then dropped by 6.98% to -$66.1 million in 2025.
- The last three Research & Development figures came in at -$66.1 million (Q4 2025), $10.6 million (Q3 2025), and $9.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -58.00 Mn |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | -66.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -66.14 Mn |
| Sep 30, 2025 | 10.57 Mn |
| Jun 30, 2025 | 8.96 Mn |
| Mar 31, 2025 | 7.85 Mn |
| Dec 31, 2024 | -61.83 Mn |
| Sep 30, 2024 | 8.40 Mn |
| Jun 30, 2024 | 9.76 Mn |
| Mar 31, 2024 | 8.66 Mn |
| Dec 31, 2023 | 8.25 Mn |
| Sep 30, 2023 | 7.09 Mn |
| Jun 30, 2023 | 7.18 Mn |
| Mar 31, 2023 | 7.31 Mn |
| Dec 31, 2022 | 6.91 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 4.24 Mn |
| Mar 31, 2022 | -4.71 Mn |
| Dec 31, 2021 | 13.76 Mn |
| Sep 30, 2021 | -2.56 Mn |
| Jun 30, 2021 | -1.95 Mn |
| Mar 31, 2021 | -692,000.00 |